Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Mental Disease

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2044621

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2044621

Insomnia Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 201 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global Insomnia Market is expanding steadily as sleep disorders gain greater clinical, social, and commercial attention. The market is valued at US$ 5.6 Bn in 2026 and is projected to reach US$ 9.1 Bn by 2033, growing at a CAGR of 7.30% during the forecast period. Insomnia, which involves difficulty initiating sleep, maintaining sleep, or achieving restorative rest, has become a major concern across age groups due to stress, lifestyle changes, mental health conditions, chronic illnesses, and irregular work patterns. As patients increasingly recognize the impact of poor sleep on productivity, emotional health, immunity, and long-term wellness, demand for effective treatment options is rising. Healthcare providers are also placing greater emphasis on sleep assessment as part of routine care, creating stronger opportunities for drug manufacturers, sleep clinics, pharmacies, and digital health platforms.

Market Insights

The Insomnia Market is supported by a wide treatment ecosystem that includes pharmacological therapy and non-pharmacological therapy. Pharmacological therapy continues to hold strong relevance, particularly for patients requiring short-term symptom relief or structured treatment for chronic insomnia. Drug classes such as benzodiazepines, non-benzodiazepines, melatonin receptor agonists, orexin receptor antagonists, antidepressants, antihistamines, herbal and natural sleep aids, and other therapies are used depending on disease severity, patient profile, safety considerations, and physician preference. At the same time, non-pharmacological therapy is gaining wider acceptance as patients seek sustainable approaches that address sleep behavior, stress management, and lifestyle-related triggers.

The market is also being influenced by changing consumer behavior. Patients are becoming more open to discussing sleep difficulties with healthcare professionals, while online pharmacies and retail pharmacies are improving access to both prescription and over-the-counter products. Homecare settings are gaining importance as many patients prefer convenient, discreet, and continuous management of sleep-related conditions. Growing interest in personalized care is encouraging companies to develop therapies that offer better tolerability, fewer dependency concerns, and improved adherence. As insomnia is often linked with anxiety, depression, pain, neurological disorders, and other comorbidities, integrated treatment strategies are becoming increasingly important.

Drivers

A key driver of the Insomnia Market is the rising prevalence of sleep disruption caused by modern lifestyles. Longer screen time, shift work, high stress levels, sedentary routines, and irregular sleep schedules are contributing to acute insomnia, chronic insomnia, comorbid insomnia, onset insomnia, and maintenance insomnia. Aging populations are also more vulnerable to sleep disturbances, increasing the need for safe and effective treatment options. In addition, the growing burden of mental health disorders is creating a strong link between psychological wellness and sleep management.

Another major driver is the advancement of drug development. Newer mechanisms, especially orexin receptor antagonists and other targeted therapies, are helping address concerns related to traditional sedative use. Physicians and patients are increasingly seeking treatment options that provide efficacy while minimizing next-day drowsiness, dependency risk, and long-term safety issues. The expansion of sleep clinics, improved diagnostic awareness, and broader availability of insomnia medications through hospital, retail, and online pharmacies are further supporting market growth.

Business Opportunity

The Insomnia Market presents strong business opportunities for pharmaceutical companies, generic drug manufacturers, specialty therapy developers, sleep clinics, and digital health providers. Companies that offer differentiated therapies with improved safety, convenient oral administration, and strong patient education support can gain competitive advantage. There is also growing potential in non-pharmacological solutions, including behavioral sleep programs, digital coaching, teleconsultation, and hybrid care models that combine medication with lifestyle support.

Online pharmacies are emerging as an important channel by offering convenient access, refill support, and privacy for patients managing recurring sleep concerns. Retail pharmacies can also strengthen their role through counseling, product guidance, and awareness initiatives. In emerging markets, rising healthcare spending, urban stress, and expanding pharmacy networks are creating new avenues for growth. Partnerships between pharmaceutical firms, sleep specialists, mental health providers, and digital platforms can help improve diagnosis, treatment adherence, and long-term patient outcomes.

Region Analysis

North America is expected to remain a leading market due to high awareness of insomnia, strong healthcare infrastructure, advanced pharmaceutical access, and widespread availability of sleep clinics. The region also benefits from active clinical research, established prescription patterns, and rising adoption of newer drug classes. Europe represents another significant market, supported by aging populations, mental health awareness, and growing focus on sleep quality as part of overall wellness.

Asia Pacific is likely to record strong growth during the forecast period, driven by urbanization, increasing work pressure, rising digital device use, and improving healthcare access. Countries such as China, India, Japan, South Korea, and Southeast Asian nations are witnessing greater awareness of sleep disorders and expanding demand for both prescription and non-prescription treatments. Latin America and the Middle East & Africa are gradually developing as pharmacy access improves, healthcare investment rises, and awareness campaigns encourage patients to seek professional care for persistent sleep problems.

Key Players

The Insomnia Market includes leading pharmaceutical companies, specialty drug developers, and generic medicine manufacturers focused on expanding treatment access and strengthening product portfolios. Key players include:

  • Eisai Co., Ltd.
  • Idorsia Ltd.
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Vanda Pharmaceuticals Inc.
  • Sumitomo Pharma Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Jazz Pharmaceuticals plc

These companies are focusing on product innovation, generic availability, clinical development, partnerships, geographic expansion, and lifecycle management. Competitive success will depend on safety profile, treatment effectiveness, physician confidence, affordability, and patient convenience.

Segmentation

By Therapy Type

  • Pharmacological Therapy
  • Non-pharmacological Therapy

By Drug Class

  • Benzodiazepines
  • Non-benzodiazepines
  • Melatonin Receptor Agonists
  • Orexin Receptor Antagonists
  • Antidepressants
  • Antihistamines
  • Herbal & Natural Sleep Aids
  • Others

By Disease Type

  • Acute Insomnia
  • Chronic Insomnia
  • Comorbid Insomnia
  • Onset Insomnia
  • Maintenance Insomnia

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User

  • Hospitals
  • Sleep Clinics
  • Homecare Settings
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global InsoBnia Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global InsoBnia Market Outlook, 2020 - 2033

  • 3.1. Global InsoBnia Market Outlook, by Therapy Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Pharmacological Therapy
    • 3.1.2. Non-pharmacological Therapy
  • 3.2. Global InsoBnia Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 3.2.1. Oral
    • 3.2.2. Parenteral
    • 3.2.3. Others
  • 3.3. Global InsoBnia Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 3.3.1. Benzodiazepines
    • 3.3.2. Non-benzodiazepines
    • 3.3.3. Melatonin Receptor Agonists
    • 3.3.4. Orexin Receptor Antagonists
    • 3.3.5. Antidepressants
    • 3.3.6. Antihistamines
    • 3.3.7. Herbal & Natural Sleep Aids
    • 3.3.8. Others
  • 3.4. Global InsoBnia Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 3.4.1. Acute InsoBnia
    • 3.4.2. Chronic InsoBnia
    • 3.4.3. Comorbid InsoBnia
    • 3.4.4. Onset InsoBnia
    • 3.4.5. Maintenance InsoBnia
  • 3.5. Global InsoBnia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.5.1. Hospital Pharmacies
    • 3.5.2. Retail Pharmacies
    • 3.5.3. Online Pharmacies
  • 3.6. Global InsoBnia Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.6.1. North America
    • 3.6.2. Europe
    • 3.6.3. Asia Pacific
    • 3.6.4. Latin America
    • 3.6.5. Middle East & Africa

4. North America InsoBnia Market Outlook, 2020 - 2033

  • 4.1. North America InsoBnia Market Outlook, by Therapy Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Pharmacological Therapy
    • 4.1.2. Non-pharmacological Therapy
  • 4.2. North America InsoBnia Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 4.2.1. Oral
    • 4.2.2. Parenteral
    • 4.2.3. Others
  • 4.3. North America InsoBnia Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 4.3.1. Benzodiazepines
    • 4.3.2. Non-benzodiazepines
    • 4.3.3. Melatonin Receptor Agonists
    • 4.3.4. Orexin Receptor Antagonists
    • 4.3.5. Antidepressants
    • 4.3.6. Antihistamines
    • 4.3.7. Herbal & Natural Sleep Aids
    • 4.3.8. Others
  • 4.4. North America InsoBnia Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 4.4.1. Acute InsoBnia
    • 4.4.2. Chronic InsoBnia
    • 4.4.3. Comorbid InsoBnia
    • 4.4.4. Onset InsoBnia
    • 4.4.5. Maintenance InsoBnia
  • 4.5. North America InsoBnia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.5.1. Hospital Pharmacies
    • 4.5.2. Retail Pharmacies
    • 4.5.3. Online Pharmacies
  • 4.6. North America InsoBnia Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.6.1. U.S. InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 4.6.2. U.S. InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 4.6.3. U.S. InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 4.6.4. U.S. InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 4.6.5. U.S. InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 4.6.6. Canada InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 4.6.7. Canada InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 4.6.8. Canada InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 4.6.9. Canada InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 4.6.10. Canada InsoBnia Market Outlook, by Distribution Channel, 2020-2033
  • 4.7. BPS Analysis/Market Attractiveness Analysis

5. Europe InsoBnia Market Outlook, 2020 - 2033

  • 5.1. Europe InsoBnia Market Outlook, by Therapy Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Pharmacological Therapy
    • 5.1.2. Non-pharmacological Therapy
  • 5.2. Europe InsoBnia Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 5.2.1. Oral
    • 5.2.2. Parenteral
    • 5.2.3. Others
  • 5.3. Europe InsoBnia Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 5.3.1. Benzodiazepines
    • 5.3.2. Non-benzodiazepines
    • 5.3.3. Melatonin Receptor Agonists
    • 5.3.4. Orexin Receptor Antagonists
    • 5.3.5. Antidepressants
    • 5.3.6. Antihistamines
    • 5.3.7. Herbal & Natural Sleep Aids
    • 5.3.8. Others
  • 5.4. Europe InsoBnia Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 5.4.1. Acute InsoBnia
    • 5.4.2. Chronic InsoBnia
    • 5.4.3. Comorbid InsoBnia
    • 5.4.4. Onset InsoBnia
    • 5.4.5. Maintenance InsoBnia
  • 5.5. Europe InsoBnia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Europe InsoBnia Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.6.1. Germany InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 5.6.2. Germany InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 5.6.3. Germany InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 5.6.4. Germany InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 5.6.5. Germany InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.6. Italy InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 5.6.7. Italy InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 5.6.8. Italy InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 5.6.9. Italy InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 5.6.10. Italy InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.11. France InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 5.6.12. France InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 5.6.13. France InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 5.6.14. France InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 5.6.15. France InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.16. U.K. InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 5.6.17. U.K. InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 5.6.18. U.K. InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 5.6.19. U.K. InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 5.6.20. U.K. InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.21. Spain InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 5.6.22. Spain InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 5.6.23. Spain InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 5.6.24. Spain InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 5.6.25. Spain InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.26. Russia InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 5.6.27. Russia InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 5.6.28. Russia InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 5.6.29. Russia InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 5.6.30. Russia InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.31. Rest of Europe InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 5.6.32. Rest of Europe InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 5.6.33. Rest of Europe InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 5.6.34. Rest of Europe InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 5.6.35. Rest of Europe InsoBnia Market Outlook, by Distribution Channel, 2020-2033
  • 5.7. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific InsoBnia Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific InsoBnia Market Outlook, by Therapy Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Pharmacological Therapy
    • 6.1.2. Non-pharmacological Therapy
  • 6.2. Asia Pacific InsoBnia Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 6.2.1. Oral
    • 6.2.2. Parenteral
    • 6.2.3. Others
  • 6.3. Asia Pacific InsoBnia Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 6.3.1. Benzodiazepines
    • 6.3.2. Non-benzodiazepines
    • 6.3.3. Melatonin Receptor Agonists
    • 6.3.4. Orexin Receptor Antagonists
    • 6.3.5. Antidepressants
    • 6.3.6. Antihistamines
    • 6.3.7. Herbal & Natural Sleep Aids
    • 6.3.8. Others
  • 6.4. Asia Pacific InsoBnia Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 6.4.1. Acute InsoBnia
    • 6.4.2. Chronic InsoBnia
    • 6.4.3. Comorbid InsoBnia
    • 6.4.4. Onset InsoBnia
    • 6.4.5. Maintenance InsoBnia
  • 6.5. Asia Pacific InsoBnia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Asia Pacific InsoBnia Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.6.1. China InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 6.6.2. China InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 6.6.3. China InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 6.6.4. China InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 6.6.5. China InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.6. Japan InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 6.6.7. Japan InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 6.6.8. Japan InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 6.6.9. Japan InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 6.6.10. Japan InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.11. South Korea InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 6.6.12. South Korea InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 6.6.13. South Korea InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 6.6.14. South Korea InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 6.6.15. South Korea InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.16. India InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 6.6.17. India InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 6.6.18. India InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 6.6.19. India InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 6.6.20. India InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.21. Southeast Asia InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 6.6.22. Southeast Asia InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 6.6.23. Southeast Asia InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 6.6.24. Southeast Asia InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 6.6.25. Southeast Asia InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.26. Rest of SAO InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 6.6.27. Rest of SAO InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 6.6.28. Rest of SAO InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 6.6.29. Rest of SAO InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 6.6.30. Rest of SAO InsoBnia Market Outlook, by Distribution Channel, 2020-2033
  • 6.7. BPS Analysis/Market Attractiveness Analysis

7. Latin America InsoBnia Market Outlook, 2020 - 2033

  • 7.1. Latin America InsoBnia Market Outlook, by Therapy Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Pharmacological Therapy
    • 7.1.2. Non-pharmacological Therapy
  • 7.2. Latin America InsoBnia Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 7.2.1. Oral
    • 7.2.2. Parenteral
    • 7.2.3. Others
  • 7.3. Latin America InsoBnia Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 7.3.1. Benzodiazepines
    • 7.3.2. Non-benzodiazepines
    • 7.3.3. Melatonin Receptor Agonists
    • 7.3.4. Orexin Receptor Antagonists
    • 7.3.5. Antidepressants
    • 7.3.6. Antihistamines
    • 7.3.7. Herbal & Natural Sleep Aids
    • 7.3.8. Others
  • 7.4. Latin America InsoBnia Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 7.4.1. Acute InsoBnia
    • 7.4.2. Chronic InsoBnia
    • 7.4.3. Comorbid InsoBnia
    • 7.4.4. Onset InsoBnia
    • 7.4.5. Maintenance InsoBnia
  • 7.5. Latin America InsoBnia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Latin America InsoBnia Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.6.1. Brazil InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 7.6.2. Brazil InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 7.6.3. Brazil InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 7.6.4. Brazil InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 7.6.5. Brazil InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.6. Mexico InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 7.6.7. Mexico InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 7.6.8. Mexico InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 7.6.9. Mexico InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 7.6.10. Mexico InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.11. Argentina InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 7.6.12. Argentina InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 7.6.13. Argentina InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 7.6.14. Argentina InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 7.6.15. Argentina InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.16. Rest of LATAM InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 7.6.17. Rest of LATAM InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 7.6.18. Rest of LATAM InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 7.6.19. Rest of LATAM InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 7.6.20. Rest of LATAM InsoBnia Market Outlook, by Distribution Channel, 2020-2033
  • 7.7. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa InsoBnia Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa InsoBnia Market Outlook, by Therapy Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Pharmacological Therapy
    • 8.1.2. Non-pharmacological Therapy
  • 8.2. Middle East & Africa InsoBnia Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 8.2.1. Oral
    • 8.2.2. Parenteral
    • 8.2.3. Others
  • 8.3. Middle East & Africa InsoBnia Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 8.3.1. Benzodiazepines
    • 8.3.2. Non-benzodiazepines
    • 8.3.3. Melatonin Receptor Agonists
    • 8.3.4. Orexin Receptor Antagonists
    • 8.3.5. Antidepressants
    • 8.3.6. Antihistamines
    • 8.3.7. Herbal & Natural Sleep Aids
    • 8.3.8. Others
  • 8.4. Middle East & Africa InsoBnia Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 8.4.1. Acute InsoBnia
    • 8.4.2. Chronic InsoBnia
    • 8.4.3. Comorbid InsoBnia
    • 8.4.4. Onset InsoBnia
    • 8.4.5. Maintenance InsoBnia
  • 8.5. Middle East & Africa InsoBnia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Middle East & Africa InsoBnia Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.6.1. GCC InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 8.6.2. GCC InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 8.6.3. GCC InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 8.6.4. GCC InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 8.6.5. GCC InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.6. South Africa InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 8.6.7. South Africa InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 8.6.8. South Africa InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 8.6.9. South Africa InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 8.6.10. South Africa InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.11. Egypt InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 8.6.12. Egypt InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 8.6.13. Egypt InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 8.6.14. Egypt InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 8.6.15. Egypt InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.16. Nigeria InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 8.6.17. Nigeria InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 8.6.18. Nigeria InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 8.6.19. Nigeria InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 8.6.20. Nigeria InsoBnia Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.21. Rest of Middle East InsoBnia Market Outlook, by Therapy Type, 2020-2033
    • 8.6.22. Rest of Middle East InsoBnia Market Outlook, by Route of Administration, 2020-2033
    • 8.6.23. Rest of Middle East InsoBnia Market Outlook, by Drug Class, 2020-2033
    • 8.6.24. Rest of Middle East InsoBnia Market Outlook, by Disease Type, 2020-2033
    • 8.6.25. Rest of Middle East InsoBnia Market Outlook, by Distribution Channel, 2020-2033
  • 8.7. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Eisai Co., Ltd.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Idorsia Ltd.
    • 9.4.3. Merck & Co., Inc.
    • 9.4.4. Takeda Pharmaceutical Company Limited
    • 9.4.5. Sanofi S.A.
    • 9.4.6. Pfizer Inc.
    • 9.4.7. Teva Pharmaceutical Industries Ltd.
    • 9.4.8. Viatris Inc.
    • 9.4.9. Vanda Pharmaceuticals Inc.
    • 9.4.10. Sumitomo Pharma Co., Ltd.
    • 9.4.11. Dr. Reddy's Laboratories Ltd.
    • 9.4.12. Lupin Limited
    • 9.4.13. Sun Pharmaceutical Industries Ltd.
    • 9.4.14. Zydus Lifesciences Ltd.
    • 9.4.15. Jazz Pharmaceuticals plc

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!